• Mashup Score: 1
    Testosterone therapy increases CVD risks for cisgender women, but not transgender adults - 10 month(s) ago

    Testosterone use increases risks for cardiovascular disease, coronary artery disease and stroke among cisgender women, but not among transgender adults, according to a study published in The Journal of Clinical Endocrinology & Metabolism. “Testosterone replacement therapy is becoming more widely accepted in women, and it is the main medical treatment for transgender males,” David

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      #ICYMI: "[The study] lays the foundation for a potential role of the use of #testosterone replacement therapy with the increasing risk of #CVD in cisgender women." #LGBTQ @DavidSLopez5 @UTMB_SPPH @CardiologyToday https://t.co/hIo6mhxzyv

  • Mashup Score: 1
    Testosterone therapy increases CVD risks for cisgender women, but not transgender adults - 10 month(s) ago

    Testosterone use increases risks for cardiovascular disease, coronary artery disease and stroke among cisgender women, but not among transgender adults, according to a study published in The Journal of Clinical Endocrinology & Metabolism. “Testosterone replacement therapy is becoming more widely accepted in women, and it is the main medical treatment for transgender males,” David

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      Cisgender women have higher risks for CVD if they use #testosterone therapy, but no increased CVD risk was observed among transgender adults. #LGBTQ @DavidSLopez5 @UTMB_SPPH @CardiologyToday https://t.co/hIo6mhxzyv

  • Mashup Score: 1
    Login - 10 month(s) ago

    New to DocMatter, or having trouble logging in? Click here to find your account Contact us for other issues, or Request to join.

    Source: www.docmatter.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheEndoSociety
      TheEndoSociety

      Your colleagues in DocMatter are discussing the case of an 18-year-old male with chronic bothersome hair loss and thinning, borderline high #testosterone levels, and morbid #obesity. After reviewing the labs, share your recommendations: https://t.co/cB6n0AyDfr

  • Mashup Score: 0
    TRAVERSE: Men using testosterone replacement do not have increased risk for CV events - 11 month(s) ago

    CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial. In data presented at ENDO 2023 and simultaneously published in The New England Journal of Medicine, the use of testosterone therapy among men aged 45 to 80 years with

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      ICYMI: “These findings of CV safety should facilitate more informed consideration of potential benefits and risks of #testosterone treatment for middle-aged and older men with #hypogonadism."#ENDO2023 @EndoMedia @TheEndoSociety @CardiologyToday https://t.co/5oRVs8fYtp

  • Mashup Score: 1
    TRAVERSE: Men using testosterone replacement do not have increased risk for CV events - 11 month(s) ago

    CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial. In data presented at ENDO 2023 and simultaneously published in The New England Journal of Medicine, the use of testosterone therapy among men aged 45 to 80 years with

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      Men with hypogonadism at high risk for #CVD who used #testosterone replacement had no difference in major adverse CV risk compared with placebo, according to findings from the TRAVERSE trial #ENDO2023 @EndoMedia @TheEndoSociety @CardiologyToday https://t.co/zt4hdH3ZHL

  • Mashup Score: 0
    Program Planner - 12 month(s) ago

    Program Planner One fine body�

    Source: www.abstractsonline.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheEndoSociety
      TheEndoSociety

      Outstanding Clinical Practitioner Award Winner | Peter J. Snyder, MD, will discuss rationale for TRAVERSE and outcomes of #testosterone treatment on clinical fractures: https://t.co/pUZy5lKJVV #ENDO2023 #endocrinology https://t.co/FriUiITw8N

  • Mashup Score: 0
    Testosterone histories from tusks reveal woolly mammoth musth episodes - Nature - 1 year(s) ago

    Comparisons of steroid hormone concentrations in dentin samples from fossil mammoth tusks with those from a modern elephant tusk provide evidence of periodic increases in testosterone in the male mammoth characteristic of musth episodes.

    Source: Nature
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NimaSharifiMD
      NimaSharifiMD

      #Testosterone in tusks and teeth! Supercool study from the groups at ⁦@UMich⁩ ⁦@UMRogelCancer⁩ and Rich Auchus! Testosterone histories from tusks reveal woolly mammoth musth episodes | Nature https://t.co/JbmEgxOnDn

Load More